Toggle light / dark theme

Dust-sized supercapacitor has voltage of AAA battery

Devices in the submillimetre range – so-called “nano-supercapacitors” – allow the shrinkage of electronic components to tiny dimensions. However, they are difficult to produce and do not usually incorporate biocompatible materials. Corrosive electrolytes, for example, can quickly discharge themselves in the event of defects and contamination.

So-called “biosupercapacitors” (BSCs) offer a solution. These have two outstanding properties: full biocompatibility, which means they can be used in body fluids such as blood, and compensation for self-discharge behaviours through bio-electrochemical reactions. In other words, they can actually benefit from the body’s own reactions. This is because, in addition to typical charge storage reactions of a supercapacitor, redox enzymatic reactions and living cells naturally present in the blood can increase the performance of a device by 40%.

Shrinking these devices down to submillimetre sizes, while maintaining full biocompatibility, has been enormously challenging. Now, scientists have created a prototype that combines both essential properties.

Estimates of Americans with long COVID-19, per state

About 11.1 million Americans are living with long COVID-19, according to new estimates from The American Academy of Physical Medicine and Rehabilitation.

Long COVID-19, or persistent symptoms up to six months after being cleared of the illness, affects around 30 percent of individuals who had COVID-19, according to two recent publications from the Journal of the American Medical Association. Symptoms of long COVID-19 are varied and may include neurological challenges, cognitive problems, shortness of breath, fatigue, pain and mobility issues.

The AAPM&R has developed a dashboard estimating long COVID-19 infections. The model assumes that 30 percent of people who recover from acute COVID-19 develop long COVID-19, but users can adjust estimates based on higher or lower percentages. U.S. case data is pulled from Baltimore-based Johns Hopkins University COVID-19 data. U.S. census data uses2019estimates.

Could bats hold the secret to healthy ageing?

In the fictional links he drew between immortal vampires and bats, Dracula creator Bram Stoker may have had one thing right.

“Maybe it’s all in the blood,” says Emma Teeling, a geneticist studying the exceptional longevity of bats in the hope of discovering benefits for humans.

The University College Dublin researcher works with the charity Bretagne Vivante to study bats living in rural churches and schools in Brittany, western France.

Dr. Harold Katcher, PhD — Chief Scientific Officer — Yuvan Research — Rejuvenative Plasma Fractions

Studying Novel Plasma Fractions For Age-Related Diseases And Systemic Rejuvenation — Dr. Harold Katcher Ph.D., Chief Scientific Officer, Yuvan Research Inc.


Dr. Harold Katcher is the Chief Scientific Officer at Yuvan Research Inc., a biotech company exploring the development of novel, young plasma fraction rejuvenation treatments in mammals.

Most recently Dr. Katcher was the Academic Director for Natural Sciences for the Asian Division of the University of Maryland Global Campus and throughout his career, Dr. Katcher has been a pioneer in the field of cancer research, and in the development of modern aspects of gene hunting and sequencing (including as one of the discoverers of the breast cancer gene BRCA1) as part of Myriad Genetics, and carries expertise in bioinformatics, chronobiology, and biotechnology.

Dr. Katcher has thousands of citations in the scientific literature, with publications ranging from protein structure to bacteriology, biotechnology, bioinformatics and biochemistry.

Dr. Katcher is launching his new book “The Illusion of Knowledge” on September 4th, 2021.

RNA technologies explained

The mRNA vaccine success story is one of the few positives to emerge from COVID-19. But these vaccines from Moderna and Pfizer/BioNTech are only the tip of the iceberg in the coming RNA medical technology revolution.

Australia, including our newly established UNSW RNA Institute, is well-placed to take a leading role in this revolution. With its eyes firmly set on making NSW a global force in the RNA industry, the NSW Government is backing a new RNA Bioscience Alliance between all the NSW Universities as well as funding a $15 million RNA production network between some of the state’s leading research organizations to bootstrap pre-clinical RNA research. UNSW’s RNA Institute is a key part of this drive, and with a $25 million investment brings together world-leading expertise to support the state and national agenda.

So beyond mRNA vaccines, what are these RNA therapeutics on the horizon? And what is the secret sauce that finally got mRNA vaccines to work after many years of trying? To understand this, let’s first tackle what RNA is and how it is used in medicine.

Altered microbiome after antibiotics in early life shown to impact lifespan

“These data suggest that differences in the microbiota following antibiotics in early life can reprogram the immune system long-term, with the consequences of this reprogramming emerging later in life, including effects on immunity, metabolism and even lifespan,” Prof Lynn said.


A team of researchers from SAHMRI and Flinders University has found a link between the type of microbiome that repopulates the gut following antibiotics and shortened lifespan in mice.

Japanese scientists produce first 3D-bioprinted, marbled Wagyu beef

The world of lab-grown meats is fast filling with all kinds of tasty bites, from burgers, to chicken breasts, to a series of increasingly complex cuts of steak. Expanding the scope of cultured beef are scientists from Japan’s Osaka University, who have leveraged cutting-edge bioprinting techniques to produce the first lab-grown “beef” that resembles the marbled texture of the country’s famed Wagyu cows.

From humble beginnings that resembled soggy pork back in 2,009 to the classic steaks and rib-eyes we’ve seen pop up in the last few years, lab-grown meat has come along in leaps and bounds. The most sophisticated examples use bioprinting to “print” living cells, which are nurtured to grow and differentiate into different cell types, ultimately building up into the tissues of the desired animal.

The Osaka University team used two types of stem cells harvested from Wagyu cows as their starting point, bovine satellite cells and adipose-derived stem cells. These cells were incubated and coaxed into becoming the different cell types needed to form individual fibers for muscle, fat and blood vessels. These were then arranged into a 3D stack to resemble the high intramuscular fat content of Wagyu, better known as marbling, or sashi in Japan.

Dr. Hanadie Yousef, Ph.D. Co-Founder & CEO — Juvena Therapeutics — Secretome Derived Therapies

Secretome Derived Regenerative Therapeutics — Dr. Hanadie Yousef Ph.D., Co-Founder & CEO, Juvena Therapeutics


Dr. Hanadie Yousef, Ph.D. is a Scientist, Co-Founder and CEO of Juvena Therapeutics (https://www.juvenatherapeutics.com/), a regenerative medicine company developing protein therapeutics to promote tissue regeneration and increase healthspan, to prevent, reverse, and cure degenerative diseases.

For over 17 years, Dr. Yousef elucidated mechanisms of aging and developed methods for tissue regeneration supported by multiple awards, fellowships and grants. Her discoveries were published in top publications that include Nature Medicine and led to several issued patents which laid the foundation of Juvena Therapeutics’ venture-backed, drug discovery and pre-clinical development platform.

Dr. Yousef earned a BS in Chemistry, summa cum laude, from Carnegie Mellon University, a PhD in Molecular and Cell Biology from UC Berkeley as an NSF graduate research fellow, pursued a 5-year postdoctoral fellowship in Neurology at Stanford School of Medicine, and conducted R&D at Regeneron and Genentech.

/* */